Literature DB >> 7523718

The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

M Ohori1, T M Wheeler, J K Dunn, T A Stamey, P T Scardino.   

Abstract

The discrepancy between the high prevalence of prostate cancer found at autopsy and the low incidence of clinical cancer prompted a study to determine whether the new diagnostic tests, that is ultrasonography and serum prostatic specific antigen (PSA) levels, detect prostate cancer at an earlier stage than the traditional test, digital rectal examination, without detecting a larger proportion of clinically unimportant cancer. Clinically detected cancer treated by radical prostatectomy (306 cases) and incidental cancer found in cystoprostatectomy specimens (90) were categorized into 3 groups by the volume, grade, extent of the cancer and outcome of treatment: clinically unimportant tumor (0.5 cm.3 or less, Gleason grades 1 to 3 and confined to the prostate), clinically important curable cancer (more than 0.5 cm.3 or grade 4 or 5 and confined, or with microscopic extracapsular extension) or advanced disease (extensive extracapsular extension, seminal vesicle invasion or lymph node metastases). Of 306 clinically detected tumors 9% were unimportant and 29% were advanced. In contrast, incidental cystoprostatectomy disease was either unimportant (78%) or curable (22%) and no tumor was advanced (p < 0.0005). Cancer detectable by digital rectal examination, ultrasonography or PSA was distributed similarly among the 3 groups. Impalpable cancer detected by PSA was less likely to be advanced (11%) than cancer detected by digital rectal examination (34%, p = 0.01) but no more likely to be unimportant (13% versus 8%). Of 29 tumors detected only by systematic biopsies because of an elevated PSA level only 4% were advanced, while 17% were unimportant. Cancer detectable with each of the available diagnostic tests was similar and differed distinctly from that found incidentally in cystoprostatectomy specimens. The detection of impalpable cancer by PSA or ultrasound decreased the proportion of advanced tumor detected without increasing significantly the detection of unimportant disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523718     DOI: 10.1016/s0022-5347(17)32369-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  32 in total

1.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Oguz Akin; Changhong Yu; Kristen L Zakian; Kazuma Udo; Peter T Scardino; James Eastham; Michael W Kattan
Journal:  BJU Int       Date:  2011-09-20       Impact factor: 5.588

2.  Best of the 2005 AUA Annual Meeting: Highlights from the 2005 Annual Meeting of the American Urological Association, May 21-May 26, 2005, San Antonio, TX.

Authors: 
Journal:  Rev Urol       Date:  2005

3.  Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Authors:  J C Alers; P J Krijtenburg; A N Vis; R F Hoedemaeker; M F Wildhagen; W C Hop; T T van Der Kwast; F H Schröder; H J Tanke; H van Dekken
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans.

Authors:  R I Sibley; A F Sibley
Journal:  J Natl Med Assoc       Date:  1997-05       Impact factor: 1.798

Review 5.  Score 3 prostate lesions: a gray zone for PI-RADS v2.

Authors:  Michele Scialpi; Eugenio Martorana; Maria Cristina Aisa; Valeria Rondoni; Alfredo D'Andrea; Giampaolo Bianchi
Journal:  Turk J Urol       Date:  2017-08-03

6.  Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.

Authors:  Zohar A Dotan; Fernando J Bianco; Farhang Rabbani; James A Eastham; Paul Fearn; Howard I Scher; Kevin W Kelly; Hui-Ni Chen; Heiko Schöder; Hedvig Hricak; Peter T Scardino; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

7.  Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.

Authors:  Gustavo E Ayala; Bahar Muezzinoglu; Kai H Hammerich; Anna Frolov; Hao Liu; Peter T Scardino; Rile Li; Mohammad Sayeeduddin; Michael M Ittmann; Dov Kadmon; Brian J Miles; Thomas M Wheeler; David R Rowley
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

8.  Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?

Authors:  S Saidi; V Georgiev; S Stavridis; D Petrovski; S Dohcev; L Lekovski; Z Popov; S Banev; G Spasovski
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

9.  Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL.

Authors:  Charles Dariane; Chloé Le Cossec; Sarah J Drouin; Benoit Wolff; Benjamin Granger; Pierre Mozer; Marc-Olivier Bitker; Shahrokh F Shariat; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-04-26       Impact factor: 4.226

10.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.